The ARSK Knockout HAP1 Polyclonal Cells product provides a validated polyclonal knockout cell population generated via CRISPR/Cas9-mediated disruption of the human ARSK gene in HAP1 cells. This loss-of-function model eliminates arylsulfatase K expression, enabling detailed investigation of sulfatase-dependent lysosomal processes. The polyclonal format ensures a diverse spectrum of edited alleles, supporting pooled assay formats and avoiding clonal bias. This product serves as a reliable tool for both targeted mechanistic studies and high-throughput screening applications.
HAP1 cells are a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells, exhibiting a predominantly haploid karyotype that simplifies genetic manipulation. These adherent fibroblast-like cells maintain stable haploidy, facilitating efficient CRISPR/Cas9 genome editing and clear genotype-phenotype relationships. The reduced genomic complexity minimizes confounding effects from diploidy, making HAP1 an ideal host for generating knockout models in functional genomics studies.
The ARSK gene encodes arylsulfatase K, a lysosomal sulfatase that hydrolyzes sulfate esters from glycosaminoglycans such as heparan sulfate and chondroitin sulfate. ARSK activity is regulated upstream by TFEB, a master transcription factor for lysosomal biogenesis, and requires post-translational activation by SUMF1. It functions downstream of these regulators within the lysosomal lumen, interacting with other hydrolases, lysosomal membrane proteins like LAMP1/2, and the lysosomal v-ATPase to mediate GAG catabolism. Disruption of ARSK thus impairs lysosomal desulfation, potentially leading to accumulation of undegraded substrates and recapitulating features of lysosomal storage disorders.
In the HAP1 background, near-haploidy ensures that CRISPR/Cas9-mediated disruption of ARSK results in complete loss of function, unmasking phenotypes that might be attenuated in diploid cells. This knockout model allows precise interrogation of ARSK’s role in lysosomal homeostasis, GAG turnover, and cellular responses to lysosomal stress. The polyclonal nature additionally enables the examination of diverse mutational outcomes, more closely mirroring the genetic heterogeneity observed in patient-derived samples and facilitating robust statistical analyses in pooled screens.
Key research applications include lysosomal storage disease modeling, functional dissection of sulfatase activation pathways, and drug discovery for enzyme replacement or chaperone therapies. Compatible assays encompass Western blotting for ARSK protein, enzymatic sulfatase activity measurements, lysosomal pH monitoring with LysoTracker, immunofluorescence for LAMP1 distribution, mass spectrometry-based glycosaminoglycan profiling, RNA-seq transcriptomics, and high-content imaging of lysosomal abnormalities. These cells are also ideal for genome-wide CRISPR screens to identify genetic modifiers of sulfatase function. For further inquiries, please contact Ascent Research.
